The Indian Invasive Anti-Fungal Drugs market size stood at around USD XX Billion in 2019 and is projected to reach USD XX Billion by 2028, exhibiting a CAGR of XX% during the forecast period (2019- 2028).
India’s tropical environment is a breeding ground for varied types of fungi and hence provides a lot of opportunities to the pharma operators to keep the drug market flooded with various anti-fungal drugs. India is the diabetic capital of the world. There are many other diseases like cancer, AIDS which are growing among the Indian population. Transplants and immunological complications are common with patients suffering from these diseases. According to AIOCD Pharmasofttech AWACS data, total anti-fungal market across categories is pegged at Rs 1069 crores, growing at XX% and XX% on units. Government’s role has also proved instrumental in driving anti-fungal drug market in India. Understanding the rising episodes of fungal infections in the country, the government employed various measures on its own including public private partnership (PPP). A growing and ageing population, increasing incidence of fungal conditions, the development and approval of new products, additional indications and formulations, and increased Indian market penetration will be driving factors for the market over the next decade.
The major factors augmenting the growth of the Invasive anti-fungal drugs market include increasing awareness about the myriad fungal infections, increasing the number of antifungal drugs available over the counter (OTC), and rising consumption of anti-fungal drugs in developing regions for a variety of medical conditions and the invasive procedures at hospitals also give rise to risk of fungal infections at an alarming rate. The other growth driver is the awareness about the myriad fungal infections that can affect the Indian patients and that the empirical or prophylaxis therapy with the standard anti-fungal drug may not suffice. The newer Invasive anti-fungals (anidulafungin etc.)